On March 4, 2022, the Department of Defense (DoD), on behalf of and in coordination with the Department of Health and Human Services (HHS), awarded a maximum $565.8 million contract to Cepheid, located in Sunnyvale, California. The award includes the company's multiplex point-of-care nucleic acid amplification tests (Xpert® Xpress SARS-CoV-2/Flu/RSV) and analyzers (GeneXpert® Xpress IV) for influenza A, influenza B, Respiratory Syncytial Virus, and SARS-CoV-2, the virus that causes COVID-19.
The Defense Logistics Agency, DoD's Defense Assisted Acquisition Cell, and HHS' Office of the Assistant Secretary for Preparedness and Response led this effort. The procurement was funded through the American Rescue Plan Act to supply critical medical resources to the nation.
